Evaluation Pipeline
Our current projects currently under evaluation
Evaluation Pipeline
Prior to in-licensing projects, ValiRx conducts a rigorous scientific and commercial evaluation of the project in question as part of our evaluation pipeline process. This period tends to be around 6-12 months, which gives ValiRx the right to assess whether the project is a good fit for the ValiRx pipeline. If the Evaluation proves to be a success, a full license will be executed to license the project into a dedicated ValiRx subsidiary.
The scientific assessment typically consists of a range of cell-based assays to understand and demonstrate the mechanism of action of the lead drug candidate, and to assess the disease area of the highest potential. The projects currently under evaluation are detailed below.
| Project | Originator | Disease | Molecule | Date Evaluation Agreement Started |
|---|---|---|---|---|
| 2022.1 | University of Barcelona (Spain) | Uterine and Pancreatic Cancers | Peptidomimetic KRAS binder | 10 February 2022 |
| 2023.1 | University of Barcelona (Spain) | Cancer (various) | KRAS (2) | 6 June 2023 |
| 2023.2 | StingRay Bio Limited (UK) | Cancer | Small Molecule | 9 November 2023 |
| 2024.1 | University of Dundee | Cancer | Pro-senescence Small Molecule | 12 February 2024 |
| 2024.2 | Imperial College London | Ovarian Cancer | Small Molecule Dual Kinase Inhibitor | 20 March 2024 |
Once the Evaluation is complete, a negotiation period is entered to set up the subsidiary and executed the license, after which the project is promoted to our in-house pipeline. Once we receive updates regarding manufacturing, product developments and formulation developments within the evaluation pipeline, we update our shareholders and this webpage accordingly.
For more information about potential collaborations and partnerships, view our partnering page.